Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook

The global market for Monoclonal Antibody (Mab) Therapeutics reached a total of $11.2 billion in 2004. The market has been growing at an impressive compound average annual growth rate of 42% over the previous five years.

The key advantage of Mab Therapeutics is their high levels of specificity for the relevant disease targets. This pinpoint specificity also serves to prevent harm to healthy cells and, hence, typically results in fewer adverse effects compared to other medicines.

Many of the leading pharmaceutical companies have entered the MAb sector, attracted by quicker and less costly development, higher success rates, premium pricing, and a potentially reduced threat from generics.

The outlook for monoclonal antibody therapeutics is healthy. The ongoing success of existing products, combined with a bulging pipeline of new products awaiting approval and limited generic erosion, point towards robust growth in this segment.

Industry participants forecast of the market vary widely, however, a consensus is emerging that the market should reach US$34 billion by the end of the decade.

Monoclonal Antibody Therapeutics - Current Market Dynamics and Future Outlook report reviews the current status of the market for monoclonal antibody therapeutics, highlights the differences between regional markets, profiles leading products and their marketing companies and discusses the different windows of opportunities opening in this market.

The report provides figures of market size, growth rates and historical evolution of the global, North American and European Mab Therapeutics markets. It also provides sales and growth rate figures for some of the leading monoclonal antibody therapeutics including: Remicade, Rituxan / MabThera, Herceptin, Synagis, Humera, Avastin, Xolair and ReoPro (Abciximab).

The report also discusses the monoclonal antibody therapeutics market outlook, growth potential, attractive areas of growth, technological innovations, products in development and consensus forecasts to the year 2010.

Written with the senior executive needs in mind, Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics.

PDF file by email: US$780

Site License: US$1,560

Print Copy: US$980

Report Code: ASI0505-4

Date Published: May 2005

Number of Pages: 42
View Table of Contents...

Price
PDF Format $780.00
Printed Copy (including shipping) $980.00
PDF Site Licence $1,560.00